[Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
Treatment with the chimeric monoclonal antibody (infliximab) is highly effective in refractory and fistulising Crohn's disease, nevertheless, infliximab resistance may occur. Authors report a 12-year-old boy with infliximab refractory luminal Crohn's disease including 3 active perianal fistulas. The patient was treated successfully with adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody. After 10 weeks of therapy, the previously high activity index returned to normal and the fistulas were closed. Quality of life using validated questionnaire improved significantly also. Adalimumab might be a suitable therapy even in pediatric Crohn's disease patients with infliximab resistance.
Veres
Gábor
G
Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Gyermekgyógyászati Klinika, Budapest. vergab@gyer1.sote.hu
Putz
Réka
R
Szabó
Dolóresz
D
Molnár
Kriszta
K
Bodánszky
Hedvig
H
Dezsofi
Antal
A
Arató
András
A
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D011788:Quality of Life; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab